Global Biopharma CEOs Frustrated By IP Waiver Talk Amid COVID-19 Vaccine Glut
Top pharma executives claim ongoing vaccine inequity is not due to a lack of supply but to a shortage of sufficient infrastructure in low-and-middle income countries to administer available doses.
